Clinical Trial Update: Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD [Phase 2]

View source ↗

Summary

Phase 2A open-label safety study of Fovista in combination with anti-VEGF therapy for sub-retinal fibrosis in neovascular age-related macular degeneration was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Fovista (E10030)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Age-related Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2019-07-10